Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas

Diagnostic Pathology

Ramziya Kiyamova¹  Valeriy Filonenko¹  Stepan Antoniuk²  Olga Kostianets³ 

[1] Department of Cell Signaling, Institute of Molecular Biology and Genetics, NAS of Ukraine, 150, Zabolotnogo str., Kyiv, Ukraine;Dnipropetrovsk Clinical Oncological Center, Dnipropetrovsk, Ukraine;Educational and Scientific Centre “Institute of Biology”, Taras Shevchenko National University of Kyiv, 64, Volodymyrs’ka Str., Kyiv, Ukraine

关键词: Breast cancer;    Expression pattern;    Tumor-associated antigen;   

Others  :  807838
DOI  :  10.1186/1746-1596-7-161

 received in 2012-08-30, accepted in 2012-11-14,  发布年份 2012

【 摘 要 】

Background

On the past decade a plethora of investigations were directed on identification of molecules involved in breast tumorogenesis, which could represent a powerful tool for monitoring, diagnostics and treatment of this disease. In current study we analyzed six previously identified medullary breast carcinoma autoantigens including LGALS3BP, RAD50, FAM50A, RBPJ, PABPC4, LRRFIP1 with cancer restricted serological profile in different histological types of breast cancer.

Methods

Semi-quantitative immunohistochemical analysis of 20 tissue samples including medullary breast carcinoma, invasive ductal carcinoma, invasive lobular carcinoma and non-cancerous tissues obtained from patients with fibrocystic disease (each of five) was performed using specifically generated polyclonal antibodies. Differences in expression patterns were evaluated considering percent of positively stained cells, insensitivity of staining and subcellular localization in cells of all tissue samples.

Results

All 6 antigens predominantly expressed in the most cells of all histological types of breast tumors and non-cancerous tissues with slight differences in intensity of staining and subcellular localization. The most significant differences in expression pattern were revealed for RAD50 and LGALS3BP in different histological types of breast cancer and for PABPC4 and FAM50A antigens in immune cells infiltrating breast tumors.

Conclusions

This pilot study made possible to select 4 antigens LGALS3BP, RAD50, PABPC4, and FAM50A as promising candidates for more comprehensive research as potential molecular markers for breast cancer diagnostics and therapy.

Virtual slides

The virtual slides’ for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1860649350796892 webcite

【 授权许可】

   
2012 Kostianets et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics. CA Cancer J Clin 2012, 62(1):10-29.
• [2]Ferlay J, Shin H-R, Bray F: Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [3]Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, Fazzari MJ, Verdier-Pinard P, Montagna C: Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res 2011, 13(4):R76. BioMed Central Full Text
• [4]Chen YT: Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immunol 2004. http://www.cance-rimmunity.org/SEREX/ webcite
• [5]Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998, 187:1349-1354.
• [6]Devitt G, Meyer C, Wiedemann N, Eichmuller S, Kopp-Schneider A, Haferkamp A, Hautmann R, Zoller M: Serological analysis of human renal cell carcinoma. Int J Cancer 2006, 118:2210-2219.
• [7]Canelle L, Bousquet J, Pionneau C, Deneux L, Imam-Sghiouar N, Caron M, Joubert-Caron R: An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods 2005, 299:77-89.
• [8]Canelle L, Bousquet J, Pionneau C, Hardouin J, Choquet-Kastylevsky G, Joubert-Caron R, Caron M: A proteomic approach to investigate potential biomarkers directed against membrane-associated breast cancer proteins. Electrophoresis 2006, 27:1609-1616.
• [9]Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M: Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 2007, 1107:223-230.
• [10]Balboni I, Chan SM, Kattah M, Tenenbaum JD, Butte AJ, Utz PJ: Multiplexed protein array plat- forms for analysis of autoimmune diseases. Annu Rev Immunol 2006, 24:391-418.
• [11]Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M: Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 2007, 104:17494-17499.
• [12]Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997, 94:1914-1918.
• [13]Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
• [14]Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992, 52:4168-4174.
• [15]Tan HT, Low J, Lim SG, Chung MC: Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276(23):6880-6904.
• [16]Utz PJ, Anderson P: Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998, 41:1152-1160.
• [17]Dittmer F, Pohlmann R, Von FK: The phosphorylation pattern of oligosaccharides in secreted procathepsin D is glycosylation site-specific and independent of the expression of mannose 6- phosphate receptors. J Biol Chem 1997, 272:852-858.
• [18]Hakomori S: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002, 99:10231-10233.
• [19]Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC, Gendler SJ: MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004, 23:5739-5747.
• [20]Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML: Level of HER2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008, 7(3):449-454.
• [21]Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004, 6(1):R24-R30. BioMed Central Full Text
• [22]Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA: Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 1991, 83(3):170-178.
• [23]Love S, King RJ: A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 1994, 69(4):743-748.
• [24]Yavelsky V, Rohkin S, Shaco-Levy R, Tzikinovsky A, Amir T, Kohn H, Delgado B, Rabinovich A, Piura B, Chan G, Kalantarov G, Trakht I, Lobel L: Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary. BMC Cancer 2008, 8:247. BioMed Central Full Text
• [25]Greene LM, Twal WO, Duffy MJ, McDermott EW, Hill AD, O’Higgins NJ, McCann AH, Dervan PA, Argraves WS, Gallagher WM: Elevated expression and altered processing of fibulin-I protein in human breast cancer. Br J Cancer 2003, 88(6):871-878.
• [26]Suzuki H, Graziano DF, McKolanis J, Finn OJ: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005, 11(4):1521-1526.
• [27]Arnold A, Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005, 23(18):4215-4224.
• [28]Nielsen NH, Arnerlöv C, Emdin SO, Landberg G: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 2001, 74(6):874-880.
• [29]Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ: Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001, 194(9):1313-1323.
• [30]Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V: Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977, 40:1365-1385.
• [31]Wargotz ES, Silverberg SG: Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 1988, 19:1340-1346.
• [32]Marginean F, Rakha EA, Ho BC, Ellis IO, Lee AH: Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol 2010, 23:1357-1363.
• [33]Hsu SM, Raine L, Nayak RN: Medullary carcinoma of breast: an immunohistochemical study of its lymphoid stroma. Cancer 1981, 48:1368-1376.
• [34]Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, Pringle GA, Zhang X, Fu L: Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast. Mod Pathol 2008, 21:1101-1107.
• [35]Kostianets O, Shyian M, Demidov S, Antoniuk S, Gout I, Filonenko V, Kiyamova R: Serological analysis of SEREX-defined medullary breast carcinoma-associated antigens. J Cancer Investig 2012, 7:519-527.
• [36]Yang XA, Dong XY, Li Y, Wang YD, Chen WF: Purification and refolding of a novel cancer/testis antigen BJ-HCC-2 expressed in the inclusion bodies of Escherichia coli. Protein Expr Purif 2004, 33(2):332-338.
• [37]Kiyamova R, Kostianets O, Malyuchik S, Filonenko V, Usenko V, Gurtovyy V, Khozayenko Y, Antonuk S, Old L, Gout I: Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach. Mol Biotechnol 2010, 46(2):105-112.
• [38]Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D’Egidio M, Natoli C, Piantelli M, Iacobelli S: 90 K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004, 19(7–9):551-556.
• [39]Dolganov GM, Maser RS, Novikov A, Tosto L, Chong S, Bressan DA, Petrini JH: Human Rad50 is physically associated with human Mre11: identification of a conserved multiprotein complex implicated in recombinational DNA repair. Mol Cell Biol 1996, 16:4832-4841.
• [40]Mazzarella R, Pengue G, Yoon J, Jones J, Schlessinger D: Differential expression of XAP5, a candidate disease gene. Genomics 1997, 45(1):216-219.
• [41]Yang H, Duckett CS, Lindsten T: iPABP, an inducible poly(A)-binding protein detected in activated human T cells. Mol Cell Biol 1995, 15:6770-6776.
• [42]Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuk A, Nakano T, Honjo T: Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immun 2002, 3:443-450.
• [43]Arakawa R, Bagashev A, Song L, Maurer K, Sullivan KE: Characterization of LRRFIP1. Biochem Cell Biol 2010, 88(6):899-906.
• [44]Ullrich A, Sures I, D’Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawver LK, Schlessinger J, Iacobelli S: The secreted tumor-associated antigen 90 K is a potent immune stimulator. J Biol Chem 1994, 269:18401-18407.
• [45]Khachigian LM, Santiago FS, Rafty LA: GC factor 2 represses platelet-derived growth factor a-chain gene transcription and is itself induced by arterial injury. Circ Res 1999, 84:1258-1267.
• [46]Suriano AR, Sanford AN, Kim N, Oh M, Kennedy S, Henderson MJ, Dietzmann K, Sullivan KE: GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol Cell Biol 2005, 25(20):9073-9081.
• [47]Simpson P, Reis-Filho J, Gale T, Lakhani S: Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
• [48]Turashvili G, Bouchal J, Ehrmann J, Fridman E, Skarda J, Kolar Z: Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007, 151(1):59-64.
• [49]Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, Kreike B, Reis-Filho JS: The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010, 220(1):45-57.
• [50]Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC: Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologistvisual scoring. Diagn Pathol 2012, 7:42. BioMed Central Full Text
• [51]Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, Laurinavicius A: Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagn Pathol 2011, 6:87. BioMed Central Full Text
• [52]Krecsák L, Micsik T, Kiszler G, Krenács T, Szabó D, Jónás V, Császár G, Czuni L, Gurzó P, Ficsor L, Molnár B: Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer. Diagn Pathol 2011, 6:6. BioMed Central Full Text
• [53]Iacobelli S, Arno E, D’Orazio A, Coletti G: Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986, 46:3005-3010.
• [54]Lee JH, Zhang X, Shin BK, Lee ES, Kim I: Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study. Pathology 2009, 41(3):229-333.
• [55]Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S: Mac-2-binding glycoproteins putative ligands for a cytosolic beta-galactoside lectin. J Biol Chem 1991, 266(28):18731-18736.
• [56]Koths K, Taylor E, Halenbeck R, Casipit C, Wang A: Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993, 268:14245-14249.
• [57]Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J: Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008, 2:296-316.
• [58]Burgess HM, Richardson WA, Anderson RC, Salaun C, Graham SV, Gray NK: Nuclear relocalisation of cytoplasmic poly(A)-binding proteins PABP1 and PABP4 in response to UV irradiation reveals mRNA-dependent export of metazoan PABPs. J Cell Sci 2011, 124:3344-3355.
• [59]Alimirah F, Panchanathany R, Davisy FJ, Cheny J, Choubey D: Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia 2007, 9:427-434.
• [60]Hu XB, Feng F, Wang YC, Wang L, He F, Dou GR, Liang L, Zhang HW, Liang YM, Han H: Blockade of Notch Signaling in Tumor-Bearing Mice May Lead to Tumor Regression, Progression, or Metastasis, Depending on Tumor Cell Types. Neoplasia 2009, 11(1):32-38.
• [61]Sakai T, Furukawa T, Iwanari H, Oka C, Nakano T, Kawaichi M, Honjo T: Loss of immunostaining of the RBP-J kappa transcription factor upon F9 cell differentiation induced by retinoic acid. J Biochem 1995, 118(3):621-628.
• [62]Zhou S, Hayward SD: Nuclear localization of CBF1 is regulated by interactions with the SMRT corepressor complex. Mol Cell Biol 2001, 21(18):6222-6232.
• [63]Krejcí A, Bray S: Notch activation stimulates transient and selective binding of Su(H)/CSL to target enhancers. Genes Dev 2007, 21(11):1322-1327.
• [64]Wacker SA, Alvarado C, von Wichert G, Knippschild U, Wiedenmann J, Clauss K, Nienhaus GU, Hameister H, Baumann B, Borggrefe T, Knöchel W, Oswald F: RITA, a novel modulator of Notch signalling, acts via nuclear export of RBP-J. EMBO J 2011, 30(1):43-56.
• [65]Soler G, Nusbaum S, Varet B, Macintyre EA, Vekemans M, Romana SP, Radford-Weiss I: LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. Leukemia 2009, 23:1359-1361.
• [66]Reed AL, Yamazaki H, Kaufman JD, Rubinstein Y, Murphy B, Johnson AC: Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor. J Biol Chem 1998, 273(34):21594-21602.
• [67]Liu YT, Yin HL: Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies. J Biol Chem 1998, 273(14):7920-7927.
• [68]Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274.